Article
FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
Rising Costs of Biologics for Plaque Psoriasis Highlight Savings Potential
Icotrokinra Shows Clear Skin in 75% of Adolescents With Plaque Psoriasis in Phase 3 Trial
Women Have Lower Drug Survival With Biologics for Psoriasis, Including IL-17 and IL-23 Inhibitors
Tildrakizumab Effective Up to Nearly 3 Years Regardless of BSA Affected, Obesity